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ABSTRACT
No abstract provided.
SUBJECT TERMS
No subject terms provided. This application proposed that HOXC gene overexpression would inhibit androgenmediated gene expression. More speculatively, it proposed further that this inhibition may predispose prostate cancer cells to become partially androgen-independent for growth even before the imposition of androgen ablation therapy. A series of experiments in cell culture models and in cell-free transcription were proposed to address these two hypotheses. Experimental data described below support the contention that androgenmediated transcription is inhibited by HOX overexpression. Curiously, the activity of the vitamin D receptor, another nuclear receptor that plays a key role in the control of prostate cancer growth, can be either inhibited or potentiated by HOXC overexpression. The data suggest that the role of HOXC overexpression on prostate cancer may be a complex one. Addressing the second hypothesis that HOXC overexpression could affect the development of androgen-independence is experimentally tricky to design in a way to adequately and appropriately test the hypothesis. To lay the groundwork for such experiments a more thorough characterization of the effects of androgens on prostate cancer lines, especially LNCaP has led to and expanded examination of the mechanisms underlying the biphasic actions of androgens on prostate cells and the complex interplay of the controls governing cell cycle and apoptosis. Specific experimental findings are described in the following section.
Key Accomplishments: W8 IXWH-04-1-0204 HOXC Family Gene Expression in Prostate Cancer: a Mechanism Contributing to Androgen Independence Task Ia. Complete. Probasin luciferase vectors were obtained from Dr. Robert Matusik and used as an androgen-dependent reporter in these studies along with a mouse mammary tumor virus luciferase reporter. Task I b. Complete. We have shown that HOXC6, HOXC8, and HOXB13 all progressively inhibit androgen receptor-mediated induction of two androgen-responsive promoters, the probasin ( Figure 1 ) and mouse mammary tumor virus promoters in LNCaP cells. This inhibition cannot be accounted for by effects of HOX genes on the expression of androgen receptors (Figure 2 ). Beyond what was proposed, we have shown that, in addition to the androgen receptor, HOXC overexpression inhibits the activity of estrogen, progesterone, and glucocorticoid receptors and that the effects of HOXC overexpression is not confined to prostate-derived cells or to epithelial cells. Task I c. Complete. We have obtained two luciferase vectors with vitamin D responsive promoters including the 24-hydroxylase promoter (cf. Figure 3) . It was proposed to begin the development of cell lines overexpressing HOX genes to assess the impact on growth in androgen-driven and androgen-deficient conditions. In order to understand the impact of HOX overexpression on androgen signaling in prostate cancer cell models, we have spent a great deal of effort more thoroughly characterizing how androgens effect the growth of the widely-used prostate cancer cell model, LNCaP. We have show that androgens have a biphasic action on these cells. At low closes, -10-30 pM, the synthetic androgen RI 881 stimulates growth but at higher doses, -1.0 nM, it inhibits growth and stimulates apoptosis of these cells (Figure 4 ). This may have clinical ramifications as it implies that incomplete androgen blockade may stimulate rather than inhibit the growth of prostate cancer. Experiments are ongoing to further characterize the biphasic actions of androgens but recent experiments indicate that we have been able to select LNCaP cell variants that are androgen-independent for growth but still retain the apoptotic response and others that are androgen-dependent for growth but do not undergo growth arrest and apoptosis at higher doses of androgen. These variants could prove to be valuable tools in elucidating the complex role of androgens in the prostate and prostate cancer. 10.00
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10-13M 10-12M 3X10-1C-11M 3X10-10M 3X10-10-AM 10-4M 12M IIM 1GM Figure 4 . Induction of nr.t g §owth in LNCaP prostate cancer cells grown in medium supplemented wAth charcoal-stripped serum plus the indicated dose of the synthetic androgen R1881. DNA content was measured after 6 days of treatment. Ford indýctxon is relative to cel-s not treated w!th R1881.
